Compare Stryker Corporation (SYK) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Stryker Corporation trades at $346.82 (market cap $133.54B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.17. The key difference: Stryker Corporation pays a 1.01% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Stryker Corporation is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| SYK | VCIT | |
|---|---|---|
Market Cap | $133.54B | — |
Sector | Technology | Fixed Income |
52-Week High | $394.34 | $84.82 |
52-Week Low | $282.58 | $81.07 |
Enterprise Value | $145.01B | — |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.20 with a slight 0.16% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund maintains consistent monthly dividend distributions, with recent payouts around $0.33-$0.34. News highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to peers like iShares corporate bond ETFs, emphasizing its cost efficiency for income-focused investors.
The outlook for VCIT is mixed, offering attractive income through corporate bond exposure but facing interest rate sensitivity. Opportunities include high relative yield and low fees, while risks involve corporate credit deterioration and Fed policy shifts. Investors should weigh yield advantages against potential volatility from economic changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
